Author of

• 11001

  +

  P1.24 - Poster Session 1 - Clinical Care (ID 146)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11019

    +

    P1.24-018 - Characteristics of patients with lung cancer with venous thromboembolism: A post hoc analysis of 676 patients enrolled to the CLOT trial (ID 1402)

    09:30 - 09:30  |  Author(s): S. Woodruff
    • Abstract

    Background
    Patients with cancer, especially those with lung cancer have an elevated risk for venous thromboembolism (VTE). Importantly, the adjusted risk of VTE is estimated to be 30 % higher among lung cancer patients undergoing chemotherapy with the majority of VTE events occurring within 6 months of initiation of chemotherapy. The presence of a VTE event is significantly associated with an increased risk of mortality[1] [1]Huang et al, J Thromb Thrombolysis. 2012 Nov;34(4):446-56. This study examines the baseline characteristics of patients with lung cancer with VTE, of the participants enrolled to the CLOT trial - a six month multi-centre study involving 676 cancer patients with acute, symptomatic, proximal deep-vein thrombosis (DVT), pulmonary embolism (PE), or both who were randomly assigned at 1:1 ratio to receive dalteparin sodium subcutaneously once daily for five to seven days and a coumarin derivative for six months (target international normalized ratio, 2.5) or dalteparin sodium alone for six months[2] [2]Lee et al N Engl J Med 2003;349:146-53.

    Methods
    Post-hoc analysis aimed at interrogating the descriptive fields of the Intention-To-Treat (ITT) CLOT trial population was conducted to determine the quantitative and qualitative base line characteristics of patients with lung cancer at randomisation.

    Results
    Of the 676 patients with cancer randomised into the CLOT trial, 90 patients had cancer of the lung. Figure 1

    Conclusion
    Baseline characteristics of patients with lung cancer with VTE as randomised in the CLOT trial indicate they were more likely to be males, under 65 years of age, had no previous VTE to the diagnosis of their lung cancer, were receiving treatment for their lung cancer, with surgical pathology and chronic immobilisation not being a significant risk factor for VTE. Review of published literature also suggests that in comparison to the non cancer population, patients with lung cancer experience significant level of pulmonary embolism[3] [3]Shinagare et al Cancer. 2011 Aug 15;117(16):3860-6